Cingulate

Cingulate

Pharmaceuticals, 1901 W. 47th Place, City, Kansas, 66205, United States, 11-50 Employees

cingulate.com

  • twitter
  • LinkedIn

phone no Phone Number: 91********

Who is CINGULATE

Cingulate is a biopharmaceutical company utilizing its innovative Precision Timed ReleaseTM (PTR) drug delivery platform technology to build and advance a pipeline of next-generation phar...

Read More

map
  • 1901 W. 47th Place, Kansas City, Kansas, 66205, United States Headquarters: 1901 W. 47th Place, Kansas City, Kansas, 66205, United States
  • 2012 Date Founded: 2012
  • 11-50 Employees: 11-50
  • dollar-icon Revenue: $10 Million to $25 Million
  • tech-icon Active Tech Stack: See technologies

industries-icon Industry: Pharmaceuticals

SIC SIC Code: 2834 | NAICS Code: 325412 | Show More

checked-icon Does something look wrong? Fix it. | View contact records from CINGULATE

Cingulate Org Chart and Mapping

Employees

Thomas Dalton

Vice President, Investor & Public Relations; Vice President, Government Affairs

Naama Courtemanche

VP, Quality Assurance and Operations

Raul Silva

Chief Science Officer

Kelly Koehn

Vice President, Clinical Operations

Raul Silva

Chief Science Officer

Lou Van Horn

Chief Financial Officer

signout-image
You are signed out

Sign in to CIENCE GO Data to uncover contact details

crown-icon Free credits every month

Frequently Asked Questions Regarding Cingulate

Answer: Cingulate's headquarters are located at 1901 W. 47th Place, City, Kansas, 66205, United States

Answer: Cingulate's phone number is 91********

Answer: Cingulate's official website is https://cingulate.com

Answer: Cingulate's revenue is $10 Million to $25 Million

Answer: Cingulate's SIC: 2834

Answer: Cingulate's NAICS: 325412

Answer: Cingulate has 11-50 employees

Answer: Cingulate is in Pharmaceuticals

Answer: Cingulate contact info: Phone number: 91******** Website: https://cingulate.com

Answer: Cingulate is a biopharmaceutical company utilizing its innovative Precision Timed ReleaseTM (PTR) drug delivery platform technology to build and advance a pipeline of next-generation pharmaceutical products. We aim to improve the lives of patients suffering from frequently diagnosed conditions characterized by burdensome daily dosing regimens and suboptimal treatment outcomes. With an initial focus on the treatment of Attention Deficit/Hyperactivity Disorder (ADHD), we believe there are multiple therapeutic areas where our PTR technology may be employed to develop additional product candidates, notably anxiety disorders.

Answer:

Premium Sales Data for Prospecting

  • Sales data across over 200M records

  • Up-to-date records (less decayed data)

  • Accurate Email Lists (real-world tested)

  • Powerful search engine and intuitive interface

lock icon Get Full Access